Kluger Malte A, Meyer Matthias C, Nosko Anna, Goerke Boeren, Luig Michael, Wegscheid Claudia, Tiegs Gisa, Stahl Rolf A K, Panzer Ulf, Steinmetz Oliver M
III. Medical Clinic, University Hospital Eppendorf, Hamburg, Germany; and.
Institute of Experimental Immunology and Hepatology, University Hospital Eppendorf, Hamburg, Germany.
J Am Soc Nephrol. 2016 Feb;27(2):454-65. doi: 10.1681/ASN.2014090880. Epub 2015 Jun 8.
Cells expressing both the regulatory T cell (Treg)-inducing transcription factor Foxp3 and the Th17 transcription factor RORγt have been identified (biTregs). It is unclear whether RORγt(+)Foxp3(+) biTregs belong to the Th17-specific Treg17 cells, represent intermediates during Treg/Th17 transdifferentiation, or constitute a distinct cell lineage. Because the role of biTregs in inflammatory renal disease is also unknown, we studied these cells in the nephrotoxic nephritis (NTN) model of acute crescentic GN. Induction of NTN resulted in rapid renal and systemic expansion of biTregs. Notably, analyses of the biTreg expression profile revealed production of both anti-inflammatory (IL-10, IL-35) and proinflammatory (IL-17) cytokines. Additionally, biTregs expressed a signature of surface molecules and transcription factors distinct from those of Th17 cells and conventional Tregs (cTregs), and biTregs were identified in Treg17-deficient mice. Finally, fate reporter and cell transfer studies confirmed that biTregs are not Treg/Th17 transdifferentiating cells. Therapeutic transfer of biTregs suppressed the development of nephritis to an extent similar to that observed with transferred cTregs, but in vitro studies indicated different mechanisms of immunosuppression for biTregs and cTregs. Intriguingely, as predicted from their cytokine profile, endogenous biTregs displayed additional proinflammatory functions in NTN that were abrogated by cell-specific deletion of RORγt. In summary, we provide evidence that RORγt(+)Foxp3(+) biTregs are a novel and independent bifunctional regulatory T cell lineage distinct from cTregs, Treg17 cells, and Th17 cells. Furthermore, biTregs appear to contribute to crescentic GN and hence may be novel therapeutic targets.
已鉴定出同时表达调节性T细胞(Treg)诱导转录因子Foxp3和Th17转录因子RORγt的细胞(双表型Treg)。尚不清楚RORγt(+)Foxp3(+)双表型Treg是属于Th17特异性Treg17细胞、代表Treg/Th17转分化过程中的中间产物,还是构成一个独特的细胞谱系。由于双表型Treg在炎症性肾脏疾病中的作用也不清楚,我们在急性新月体性肾小球肾炎的肾毒性肾炎(NTN)模型中研究了这些细胞。NTN的诱导导致双表型Treg在肾脏和全身迅速扩增。值得注意的是,对双表型Treg表达谱的分析显示其产生抗炎(IL-10、IL-35)和促炎(IL-17)细胞因子。此外,双表型Treg表达的表面分子和转录因子特征不同于Th17细胞和传统Treg(cTreg),并且在Treg17缺陷小鼠中也鉴定出了双表型Treg。最后,命运报告基因和细胞转移研究证实双表型Treg不是Treg/Th17转分化细胞。双表型Treg的治疗性转移在一定程度上抑制了肾炎的发展,类似于转移cTreg所观察到的情况,但体外研究表明双表型Treg和cTreg的免疫抑制机制不同。有趣的是,正如从其细胞因子谱所预测的那样,内源性双表型Treg在NTN中表现出额外的促炎功能,而RORγt的细胞特异性缺失可消除这些功能。总之,我们提供的证据表明,RORγt(+)Foxp3(+)双表型Treg是一种新型且独立的双功能调节性T细胞谱系,不同于cTreg、Treg17细胞和Th17细胞。此外,双表型Treg似乎参与了新月体性肾小球肾炎的发生,因此可能是新的治疗靶点。